Amarin Corp Plc (AMRN)

[sts66]

You raise an interesting point - even at max capacity Sinochem cannot supply enough API to cover all existing V scrips - can an insurer really refuse to cover an available brand name when no other drug exists to treat that indication, leaving patients at risk with no options? This is not a "matter of weeks" issue - there are vast areas in the US where GV will not be available until more generics come to market - some patients are going to go months w/o V or GV, but I'm not sure there's anything those patients can do about it. For instance, I use an inhaler when I get an asthma attack, my BP skyrockets and I get tachycardia - clearly an acute CVE risk situation, but for years no Medicare Part D plans covered inhalers, so I was SOL, had to buy it from Canada and pay out of pocket. So maybe BCBS really can say "sucks to be you if GV isn't available"?